NEW YORK - Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM), a biopharmaceutical company specializing in targeted radiotherapies, has revealed new data from its Phase 3 SIERRA trial regarding Iomab-B, a treatment for acute myeloid leukemia (AML).
The findings, presented at the 2024 Tandem Meetings of ASTCT and CIBMTR, show significant survival benefits for patients aged 65 and over with active relapsed or refractory AML.
Patients in this age group typically face poor prognosis due to multiple comorbidities and high-risk cytogenetics, often making them ineligible for bone marrow transplant (BMT). However, the SIERRA trial data indicates that Iomab-B led BMTs have achieved a 100% success rate in access and engraftment for evaluable patients, despite their high leukemia burden and history of multiple treatments.
Dr. Rajneesh Nath, a leading figure in stem cell transplant and leukemia, highlighted that Iomab-B's targeted conditioning is well tolerated, even in patients with advanced age and multiple comorbidities.
Importantly, the treatment has shown to provide access to potentially curative transplants for a substantially greater number of patients compared to the control arm. Iomab-B recipients experienced higher rates of complete remission, and notably, only those treated with Iomab-B achieved 1-year and 2-year survival rates.
The trial outcomes are particularly noteworthy for patients with TP53 mutations, which are generally associated with poor survival outcomes. The control arm, which included approved therapies targeting FLT3 and IDH mutations and venetoclax, a BCL-2 inhibitor, did not see any patients survive beyond one year.
Actinium's Chairman and CEO, Sandesh Seth, expressed excitement over the results, stating that Iomab-B led BMT improved outcomes across all major patient segments, including those with advanced age, comorbidities, treatment-resistant disease, and high-risk features. The company is focused on making Iomab-B available to patients globally as quickly as possible.
Actinium Pharmaceuticals continues to develop targeted radiotherapies, with Iomab-B being prepared for broader applications in other blood cancers and Iomab-ACT aimed at improving cell and gene therapy outcomes. The company holds an extensive patent portfolio, which includes several patents related to the manufacture of the isotope Ac-225.
This news is based on a press release statement and reflects the company's ongoing efforts to address significant unmet needs in the treatment of AML.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.